Place du test de génération de thrombine dans les maladies auto-immunes

Billoir, Paul; Miranda, S.; Benhamou, Y.

doi:10.1016/j.revmed.2021.06.006

Cited by 4 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No study has yet evaluated the association of D-dimer with CVST clinical manifestations. Besides, thrombin generation (TG) has been proposed as a global assay to evidence hypocoagulable [ 10 , 11 ] and hypercoagulable states [ [12] , [13] , [14] ]: increased TG is an independent predictor of recurrent venous thrombosis [ 15 ]. Inflammation biomarkers, such as fibrinogen and high-sensitivity C-reactive protein (hs-CRP), have been recently described as possible predictors of poor prognosis in CVST [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

C-reactive protein and D-dimer in cerebral vein thrombosis: Relation to clinical and imaging characteristics as well as outcomes in a French cohort study

Billoir¹,

Siguret²,

Fron³

et al. 2023

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

C-reactive protein and D-dimer in cerebral vein thrombosis: Relation to clinical and imaging characteristics as well as outcomes in a French cohort study

Billoir¹,

Siguret²,

Fron³

et al. 2023

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

“…Thrombin generation assay (TGA) is used to measure of thrombin production, which is effective in both procoagulant and anticoagulant systems. Previous studies have shown that TGA can be used to demonstrate a tendency to hypercoagulability in myocardial infarction, antiphospholipid antibody syndrome, and in patients with protein C, protein S, antithrombin III deficiency 6–9 …”

Section: Introductionmentioning

confidence: 99%

“…Previous studies have shown that TGA can be used to demonstrate a tendency to hypercoagulability in myocardial infarction, antiphospholipid antibody syndrome, and in patients with protein C, protein S, antithrombin III deficiency. [6][7][8][9] The aim of the present study was to determine the tendency to hypercoagulability and the changes occurring with treatment by measuring thrombin with TGA test in platelet-poor plasma before and after oral iron replacement in pediatric patients diagnosed with IDA.…”

mentioning

confidence: 99%

Thrombin generation assay in platelet‐poor plasma in children with iron deficiency anemia

Özdöl,

Özdemir,

Töret

et al. 2023

Int J Lab Hematology

View full text Add to dashboard Cite

ObjectivesIron deficiency anemia (IDA) is the most common type of anemia in childhood and it leads to a hypercoagulable state. We investigated endogenous thrombin production in platelet‐poor plasma before and after oral iron replacement in children with IDA using the thrombin generation assay (TGA).MethodsA total of 72 children diagnosed with IDA (IDA group) and 60 healthy children (control group) were included in the study. Blood samples were collected from the patients before and 1 month after oral iron replacement. TGA parameters [lag time, time to peak, peak height, endogenous thrombin potential (ETP)] were studied.ResultsIn the IDA group, the lag time and time to peak decreased by 8.3% and 10.6%, respectively, and the endogenous thrombin potential (ETP) and peak height both increased by 30% compared to those of the control group. Compared to the values before iron replacement, 1 month after iron replacement, the lag time and time to peak increased by 8.7% and 5%, respectively, and the ETP and peak height decreased by 31% and 31.3%, respectively, and became similar to those of the control group.ConclusionChildren with IDA have increased endogenous thrombin production in platelet‐poor plasma and a tendency for hypercoagulability. These changes are reversible, and the ETP values become similar to those of healthy children 1 month after iron replacement.

show abstract

Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients

Bradáčová,

Slavík,

Úlehlová

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The aim of this study was to determine the thrombogenicity of lupus anticoagulant (LA) antibodies using a modified thrombin generation assay (TGA) with the addition of activated protein C (APC) in a group of 85 patients with LA-positive samples. Of these, 58 patients had clinical manifestations of antiphospholipid syndrome (APS) according to the Sydney criteria classification, i.e., each patient had thrombosis or foetal loss, and 27 patients did not show any clinical manifestations of APS. A comparison of the two groups’ TGA results revealed statistically significant differences (Fisher’s test p = 0.0016). The group of patients exhibiting clinical manifestations of APS showed higher thrombogenicity in 56.9% of patients, while the group of patients not yet exhibiting clinical manifestations of APS showed higher thrombogenicity in 25.9% of patients. There were no significant differences in the specificity of the TGA test between the groups of patients exhibiting similar clinical manifestations. Receiver operating characteristic curve analysis showed a more significant relationship (p = 0.0060) for TGA than for LA titre (p = 0.3387). These data suggest that the determination of LA thrombogenicity with the TGA assay leads to an increased prediction of the manifestation of a thromboembolic event. Our findings appear to be particularly relevant for the prediction of thrombotic events in patients with laboratory-expressed APS and no clinical manifestations.

show abstract

Place du test de génération de thrombine dans les maladies auto-immunes

Cited by 4 publications

References 55 publications

C-reactive protein and D-dimer in cerebral vein thrombosis: Relation to clinical and imaging characteristics as well as outcomes in a French cohort study

C-reactive protein and D-dimer in cerebral vein thrombosis: Relation to clinical and imaging characteristics as well as outcomes in a French cohort study

Thrombin generation assay in platelet‐poor plasma in children with iron deficiency anemia

Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients

Contact Info

Product

Resources

About